The effect of tandospirone, a serotonin1A agonist, on memory function in schizophrenia

Serotonin and Schizophrenia

“…) clozapine increases dopamine release in the PFC via its 5-HT 1A agonism (Rollema et al, 1997). In support of this hypothesis, Sumiyoshi et al (Sumiyoshi et al, 2001a(Sumiyoshi et al, , 2001b reported that chronic administration of the selective 5-HT 1A receptor agonist tandospirone as a co-therapy with typical antipsychotics enhance verbal memory and executive functions in schizophrenia patients. In contrast, chronic co-administration of the 5-HT 1A receptor partial agonist buspirone with atypical antipsychotics improved psychomotor speed but not memory or executive function in schizophrenia patients (Sumiyoshi et al, 2007).…”

Serotonin-1A Receptors and Cognitive Enhancement in Schizophrenia: Role for Brain Energy Metabolism

“…The addition of tandospirone (30 mg/day), but not placebo, to typical antipsychotic drugs (mainly haloperidol) for 4-6 weeks, was found to improve verbal memory (effect size = 0.70), memory organization, and executive function (0.63) (Sumiyoshi T. et al 2000, Sumiyoshi T. et al 2001a, Sumiyoshi T. et al 2001b). …”

“…summarizes the mode of actions (agonism or antagonism) and specific compounds related to the above-mentioned 5-HT receptor subtypes. Among them, 5-HT 1A receptor stimulation is currently considered as the most promising approach (Llado-Pelfort et al 2011, Newman-Tancredi and Kleven 2011, Newman-Tancredi and Albert in press, Sumiyoshi C. et al 2006, Sumiyoshi T. et al 2007a, Sumiyoshi T. et al 2000, Sumiyoshi T. et al 2007b, Sumiyoshi T. et al 2001a, Sumiyoshi T. et al 2001b), as discussed in the next section. This is followed by 5-HT 2A antagonism, as elicited by certain (although not satisfactory) efficacy of a series of AAPDs whose principal pharmacologic feature is blockade of 5-HT 2A receptors (Meltzer et al 1989, Meltzer and Massey 2011, Stockmeier et al 1993, Sumiyoshi T. et al 1995.…”

“…This is followed by 5-HT 2A antagonism, as elicited by certain (although not satisfactory) efficacy of a series of AAPDs whose principal pharmacologic feature is blockade of 5-HT 2A receptors (Meltzer et al 1989, Meltzer and Massey 2011, Stockmeier et al 1993, Sumiyoshi T. et al 1995. Recent evidence from animal models of schizophrenia suggests the advantage of agonists at 5-HT 6 or 5-HT 7 receptors for ameliorating memory impairment, as revealed by behavioral experiments using antagonist at the N-methyl-D-aspartate (NMDA) type of Glu receptors , Meltzer and Massey 2011 Harvey et al 2011;Kern et al 2006;Llado-Pelfort et al 2010Meltzer et al 2011;Meltzer and Massey 2011;Newman-Tancredi 2011, in press;Sumiyoshi et al 2000Sumiyoshi et al , 2001aSumiyoshi et al , 2001bSumiyoshi et al , 2006Sumiyoshi et al , 2007aSumiyoshi et al , 2007bSumiyoshi et al , 2008Sumiyoshi et al , 2009 …”

“…The interest in the 5-HT 1A receptor in relation to cognition in schizophrenia was founded by a series of pilot studies of the effects of augmentation therapy with tandospirone, a 5-HT 1A partial agonist, in patients treated with antipsychotic drugs (Sumiyoshi T. et al 2000, Sumiyoshi T. et al 2001a, Sumiyoshi T. et al 2001b). The addition of tandospirone (30 mg/day), but not placebo, to typical antipsychotic drugs (mainly haloperidol) for 4-6 weeks, was found to improve verbal memory (effect size = 0.70), memory organization, and executive function (0.63) (Sumiyoshi T. et al 2000, Sumiyoshi T. et al 2001a, Sumiyoshi T. et al 2001b).…”